Indirect‐response model for the time course of leukopenia with anticancer drugs

Because both the nadir count and the duration of leukopenia after chemotherapy with anti‐cancer drugs are important, a pharmacodynamic model describing the entire time course of leukopenia is valuable. In this study, a pharmacodynamic model was developed to simulate leukopenia.

[1]  V P BOND,et al.  GRANULOCYTOPOIESIS. II. EMERGENCE AND PATTERN OF LABELING OF NEUTROPHILIC GRANULOCYTES IN HUMANS. , 1964, Blood.

[2]  M. Marty,et al.  Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. , 1993, Cancer research.

[3]  L B Sheiner,et al.  A population model for the leukopenic effect of etoposide , 1995, Clinical pharmacology and therapeutics.

[4]  L. Grochow,et al.  Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. , 1994, Cancer research.

[5]  W J Jusko,et al.  Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects , 1989, Clinical pharmacology and therapeutics.

[6]  E. Endert,et al.  Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man. , 1984, The Journal of pharmacology and experimental therapeutics.

[7]  George E. Cartwright,et al.  Analytical Review: The Kinetics of Granulopoiesis in Normal Man , 1964 .

[8]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[9]  M. Egorin,et al.  Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. , 1984, Cancer research.

[10]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[11]  R. Larsson,et al.  A general model for time‐dissociated pharmacokinetic‐pharmacodynamic relationships exemplified by paclitaxel myelosuppression , 1998, Clinical pharmacology and therapeutics.

[12]  D G Lowe,et al.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Ratain,et al.  Modeling interpatient pharmacodynamic variability of etoposide. , 1991, Journal of the National Cancer Institute.

[14]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .

[15]  H. Saka,et al.  Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. C. Dubbelman,et al.  Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L B Sheiner,et al.  Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.

[18]  K. Eguchi,et al.  Phase I and Pharmacokinetic Study of Paclitaxel by 24‐Hour Intravenous Infusion , 1994, Japanese journal of cancer research : Gann.

[19]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Mauer,et al.  LEUKOKINETIC STUDIES. II. A METHOD FOR LABELING GRANULOCYTES IN VITRO WITH RADIOACTIVE DIISOPROPYLFLUOROPHOSPHATE (DFP). , 1960, The Journal of clinical investigation.

[21]  K. Shimokata,et al.  Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Schilsky,et al.  Pharmacodynamics in cancer therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Egorin,et al.  Paclitaxel pharmacokinetics and pharmacodynamics. , 1995, Seminars in oncology.

[24]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.

[25]  I. Boll,et al.  Granulocytopoiesis in human bone marrow cultures studied by means of kinematography. , 1965, Blood.

[26]  M. Ratain,et al.  Individualizing dosing of cancer chemotherapy. , 1993, Seminars in oncology.

[27]  M. Ratain,et al.  Pharmacodynamic modeling of prolonged administration of etoposide , 1996, Cancer Chemotherapy and Pharmacology.

[28]  P. Müller,et al.  Pharmacodynamic analysis of hematologic profiles , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[29]  M M WINTROBE,et al.  THE KINETICS OF GRANULOPOIESIS IN NORMAL MAN. , 1964, Blood.

[30]  N. Saijo,et al.  Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.